Heart failure & cardiomyopathies
Global real-world data on heart failure with reduced ejection fraction: challenges in optimization and sex disparities
Authors' conclusion
Clinical inertia remains a critical issue, especially in those who may most benefit from HF therapy.
Study context
- Population
- Patients with heart failure with reduced ejection fraction (HFrEF) worldwide68% men
- Participants
- 17,668 patients
- Exposure
- Number of guideline-directed medical therapies (GDMT) classes prescribed
- Outcome
- All-cause mortality
Methodological detailsmultinational real-world database (TriNetX)
- Multinational real-world database (TriNetX)
Main finding
As reported in the abstract
- Each additional heart failure (HF) therapy class associated with significant mortality reduction
- P-value < 0.001 for each additional class prescribed
Observational data: associations, not effects.
Further findings
GDMT prescription
- Quadruple therapy received
- 20%
- MRA prescribed
- 39%
- SGLT2 inhibitors prescribed
- 33%
- Least prescribed especially among older and frail patients
Mortality by time to quadruple therapy within first year (G4)
- Timing of full treatment implementation within the first year did not significantly affect mortality
Survival by sex (age-matched subgroup)
- No significant sex-based differences in survival
- Age-matched analysis
Original publication
Global real-world data on heart failure with reduced ejection fraction: challenges in optimization and sex disparities. Eur Heart J Qual Care Clin Outcomes. Published 3 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →